Zevra Therapeutics (ZVRA) Capital Expenditures Growth (3y) (2017 - 2026)
Zevra Therapeutics (ZVRA) Capital Expenditures Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Zevra Therapeutics | 570.04 Mn | 369.43 Mn | 34.32 Mn | 6.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.47% |
| Dec 31, 2025 | 58.85% |
| Sep 30, 2025 | 170.47% |
| Jun 30, 2025 | -72.74% |
| Mar 31, 2025 | 26.19% |
| Dec 31, 2023 | 40.43% |
| Jun 30, 2023 | 97.18% |
| Mar 31, 2023 | 93.54% |
| Dec 31, 2022 | -349.79% |
| Sep 30, 2022 | 91.29% |
| Mar 31, 2022 | -752.16% |
| Dec 31, 2021 | 4.26% |
| Dec 31, 2020 | 105.41% |
| Jun 30, 2020 | -59.15% |
| Mar 31, 2020 | -65.69% |
| Dec 31, 2019 | -61.70% |
| Sep 30, 2019 | -77.14% |
| Mar 31, 2019 | -36.37% |
| Dec 31, 2018 | -27.89% |
| Dec 31, 2017 | -52.50% |